Improvement of Transdermal Delivery of Exendin-4 Using Novel Tip-Loaded Microneedle Arrays Fabricated from Hyaluronic Acid.

The purpose of this study was to evaluate the characteristics of exendin-4 tip-loaded microneedle arrays and to compare their acute efficacy with subcutaneous injections in type 2 diabetic GK/Slc rats. Fluorescein isothiocyanate labeled dextran with an average molecular weight of 4,000 (FD4) was selected as a model drug, and FD4 tip-loaded microneedle arrays were prepared in this study. In addition, intraperitoneal glucose tolerance tests after application of exendin-4 tip-loaded microneedle arrays were also compared with those after subcutaneous injection in type 2 diabetic GK/Slc rats. The release of FD4 from the tip-loaded microneedle arrays was very rapid, particularly in the initial 30 s, and most of the FD4 was released within 5 min. In addition, glucose tolerance was improved and the insulin secretion was enhanced after application of exendin-4 tip-loaded microneedle arrays, and these effects were comparable to those after subcutaneous injection of exendin-4. Similar plasma concentration profiles were seen after application of exendin-4 tip-loaded microneedle arrays, as was the case with subcutaneous injection in type 2 diabetic GK/Slc rats. These findings indicate that exendin-4 tip-loaded microneedle arrays can be used as an alternative to achieve sufficient delivery of exendin-4 for treatment of type 2 diabetes. To our knowledge, this is the first report of transdermal exendin-4 delivery using tip-loaded microneedle arrays.

[1]  R. Kawamori,et al.  Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents. , 2009, Biochemical and biophysical research communications.

[2]  Dennis D. Kim,et al.  Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. , 2003, The Journal of clinical endocrinology and metabolism.

[3]  S. Bloom,et al.  Incretins and other peptides in the treatment of diabetes , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[4]  M. Sasaki,et al.  Development of diabetes in the non-obese NIDDM rat (GK rat). , 1988, Advances in experimental medicine and biology.

[5]  B. Gallwitz.  New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. , 2005, The review of diabetic studies : RDS.

[6]  Jung-Hwan Park,et al.  Dissolving microneedles for transdermal drug delivery. , 2008, Biomaterials.

[7]  S. Chae,et al.  A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[8]  Yoshinori Onuki,et al.  Current challenges in non-invasive insulin delivery systems: a comparative review. , 2007, Advanced drug delivery reviews.

[9]  R. Bergman,et al.  Exenatide Sensitizes Insulin-Mediated Whole-Body Glucose Disposal and Promotes Uptake of Exogenous Glucose by the Liver , 2009, Diabetes.

[10]  Dennis D. Kim,et al.  Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[11]  A. Young,et al.  Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. , 2001, Metabolism: clinical and experimental.

[12]  J. Bouwstra,et al.  Assembled microneedle arrays enhance the transport of compounds varying over a large range of molecular weight across human dermatomed skin. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[13]  A. Barnett,et al.  Inhaled insulin: new technology, new possibilities , 2006, International journal of clinical practice.

[14]  S. Efendić,et al.  The incretin hormones GIP and GLP‐1 in diabetic rats: effects on insulin secretion and small bowel motility , 2009, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[15]  J. Egan,et al.  Mechanisms of action of glucagon-like peptide 1 in the pancreas. , 2007, Pharmacology & therapeutics.

[16]  Yuanguo Cheng,et al.  Single- and multiple-dose pharmacokinetics of exendin-4 in rhesus monkeys. , 2008, International journal of pharmaceutics.

[17]  Wijaya Martanto,et al.  Mechanism of fluid infusion during microneedle insertion and retraction. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[18]  Akira Yamamoto,et al.  The development and characteristics of novel microneedle arrays fabricated from hyaluronic acid, and their application in the transdermal delivery of insulin. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[19]  A. Young,et al.  Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes , 2004, Regulatory Peptides.

[20]  Risto S. Cvetković,et al.  Exenatide , 2012, Drugs.

[21]  B. Portha,et al.  Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. , 2002, Diabetes.

[22]  H. Katsumi,et al.  Development of a novel self-dissolving microneedle array of alendronate, a nitrogen-containing bisphosphonate: evaluation of transdermal absorption, safety, and pharmacological effects after application in rats. , 2012, Journal of pharmaceutical sciences.

[23]  W. Shim,et al.  Efficacy of a new sustained-release microsphere formulation of exenatide, DA-3091, in Zucker diabetic fatty (ZDF) rats. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[24]  Takaya Miyano,et al.  Sugar Micro Needles as Transdermic Drug Delivery System , 2005, Biomedical microdevices.

[25]  K. Soppimath,et al.  Novel delivery technologies for protein and peptide therapeutics. , 2006, Current pharmaceutical biotechnology.

[26]  N. Greig,et al.  Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. , 2000, Endocrinology.

[27]  W. Shim,et al.  Pharmacokinetics and Efficacy of a Biweekly Dosage Formulation of Exenatide in Zucker Diabetic Fatty (ZDF) Rats , 2009, Pharmaceutical Research.

[28]  Mark R. Prausnitz,et al.  Dissolving Polymer Microneedle Patches for Influenza Vaccination , 2010, Nature Medicine.

[29]  Ryan F. Donnelly,et al.  Design, Optimization and Characterisation of Polymeric Microneedle Arrays Prepared by a Novel Laser-Based Micromoulding Technique , 2010, Pharmaceutical Research.

[30]  J. Leahy.  Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes , 2008 .

[31]  Dennis D. Kim,et al.  The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes , 2007, Annals of Internal Medicine.

[32]  Chandra Sekhar Kolli,et al.  Characterization of Solid Maltose Microneedles and their Use for Transdermal Delivery , 2007, Pharmaceutical Research.

[33]  S. Woods,et al.  Arcuate Glucagon-Like Peptide 1 Receptors Regulate Glucose Homeostasis but Not Food Intake , 2008, Diabetes.

[34]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[35]  S. Woods,et al.  Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. , 2007, Endocrinology.

[36]  B. Hartmann,et al.  Long‐term exendin‐4 treatment delays natural deterioration of glycaemic control in diabetic Goto–Kakizaki rats , 2009, Diabetes, obesity & metabolism.

[37]  Conor O'Mahony,et al.  Processing difficulties and instability of carbohydrate microneedle arrays , 2009, Drug development and industrial pharmacy.

[38]  S. Chae,et al.  Preparation and structural, biochemical, and pharmaceutical characterizations of bile acid-modified long-acting exendin-4 derivatives. , 2009, Journal of medicinal chemistry.